Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Werewolf Therapeutics (HOWL)
NASDAQ:HOWL
RESEARCH TOOLSreports
Werewolf Therapeutics (HOWL) Stock Price & Analysis
160 Followers
HOWL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.57 - $8.19
Previous Close$2.72
Volume178.14K
Average Volume (3M)318.04K
Market Cap
$118.20M
Enterprise Value$30.27M
Total Cash (Recent Filing)$139.20M
Total Debt (Recent Filing)$51.27M
Price to Earnings (P/E)―
Beta0.70
Next Earnings
Aug 08, 2024EPS Estimate
-$0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.09
Shares Outstanding43,455,367
10 Day Avg. Volume261,932
30 Day Avg. Volume318,044
Standard Deviation0.27
R-Squared0.01
Alpha-0.00541
Financial Highlights & Ratios
Price to Book (P/B)1.06
Price to Sales (P/S)150.06
Price to Cash Flow (P/CF)-2.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.81
Enterprise Value/Gross Profit19.38
Enterprise Value/Ebitda-0.89
Forecast
1Y Price Target
$11.50Price Target Upside322.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Werewolf Therapeutics News
PremiumCompany Announcements
Werewolf Therapeutics Reports Promising WTX-330 Trial Outcomes
PremiumCompany Announcements
Werewolf Therapeutics’ Promising WTX-124 Clinical Trial Outcomes
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyWTX-124 achieved 1 durable complete response and 2 partial responses in a primary CPI refractory SCC patient as a monotherapy.
Investment OpportunityInitial data showcased the safety of WTX-330, a partnership with Jazz Pharmaceuticals, and a cash position at $125.4MM, representing a unique investment opportunity.
Safety ProfileNo Grade 4 or Grade 5 related adverse events have been seen, with most patients experiencing only mild to moderate toxicities.
Bears Say
Competitive ChallengeEmerging next-generation IL-2 competition, including two with data at ASCO, poses a competitive challenge.
Efficacy ConcernsShares are down meaningfully, likely due to concerns about the strength of the efficacy outcomes relative to recent competitor data.
Patient ProgressionA melanoma patient dosed at 12 mg with a previous unconfirmed PR unfortunately progressed at week 16.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
HOWL FAQ
What was Werewolf Therapeutics’s price range in the past 12 months?
Werewolf Therapeutics lowest stock price was $1.57 and its highest was $8.19 in the past 12 months.
What is Werewolf Therapeutics’s market cap?
Currently, no data Available
When is Werewolf Therapeutics’s upcoming earnings report date?
Werewolf Therapeutics’s upcoming earnings report date is Aug 08, 2024 which is in 18 days.
How were Werewolf Therapeutics’s earnings last quarter?
Werewolf Therapeutics released its earnings results on May 03, 2024. The company reported -$0.39 earnings per share for the quarter, missing the consensus estimate of -$0.342 by -$0.048.
Is Werewolf Therapeutics overvalued?
According to Wall Street analysts Werewolf Therapeutics’s price is currently Undervalued.
Does Werewolf Therapeutics pay dividends?
Werewolf Therapeutics does not currently pay dividends.
What is Werewolf Therapeutics’s EPS estimate?
Werewolf Therapeutics’s EPS estimate is -$0.38.
How many shares outstanding does Werewolf Therapeutics have?
Werewolf Therapeutics has 43,455,368 shares outstanding.
What happened to Werewolf Therapeutics’s price movement after its last earnings report?
Werewolf Therapeutics reported an EPS of -$0.39 in its last earnings report, missing expectations of -$0.342. Following the earnings report the stock price went down -0.164%.
Which hedge fund is a major shareholder of Werewolf Therapeutics?
Among the largest hedge funds holding Werewolf Therapeutics’s share is RA Capital Management. It holds Werewolf Therapeutics’s shares valued at 40M.
---
Werewolf Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.50 (322.79% Upside)
$11.50 (322.79% Upside)
Blogger Sentiment
Bullish
HOWL Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 37.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.4%
Last 30 Days ▼ 8.2%
Last 30 Days ▼ 8.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-18.80%
12-Months-Change
Fundamentals
Return on Equity
-34.84%
Trailing 12-Months
Asset Growth
-8.96%
Trailing 12-Months
Company Description
Werewolf Therapeutics
Werewolf Therapeutics Inc is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer.
---
HOWL Stock 12 Month Forecast
Average Price Target
$11.50
▲(322.79% Upside)
Technical Analysis
Aldeyra Therapeutics
―
Intra-Cellular Therapies
―
Xeris Pharmaceuticals
―
Intellia Therapeutics
―
Best Analysts Covering HOWL
1 Year
1 Year Success Rate
8/14 ratings generated profit
1 Year Average Return
+8.59%
reiterated a buy rating 20 days ago
Copying Andres Y. Maldonado's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +8.59% per trade.
---